Status:

COMPLETED

Comparison of Post- and Pre-dilutional Hemodiafiltration in Hemodialysis Patients

Lead Sponsor:

Tungs' Taichung Metroharbour Hospital

Conditions:

Hemodiafiltration

Eligibility:

All Genders

20+ years

Brief Summary

Hemodiafiltration (HDF) is a choice of treatment modalities for patients with end-stage renal disease. Hemodiafiltration, combining diffusion and convection, may increase removal of large and middle m...

Detailed Description

1. Study design: randomly assigned, cross-over study. 2. Patient number: 60. 3. Inclusion criteria: stable patients end-stage renal disease who were older than 20 years and received thrice-weekly stan...

Eligibility Criteria

Inclusion

  • stable patients end-stage renal disease who were older than 20 years and received thrice-weekly standard hemodialysis for more than 3 months were recruited.

Exclusion

  • active systemic disease, liver cirrhosis, malignancy, receiving immunosuppressive treatment, dialysis with temporal non-tunneled catheter, inadequate dialysis dose (kt/V\<1.2).

Key Trial Info

Start Date :

September 1 2017

Trial Type :

OBSERVATIONAL

Allocation :

ACTUAL

End Date :

April 7 2019

Estimated Enrollment :

49 Patients enrolled

Trial Details

Trial ID

NCT03288285

Start Date

September 1 2017

End Date

April 7 2019

Last Update

April 23 2019

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Tungs' Taichung Metroharbour Hospital

Taichung, Taiwan